Marianne Nordsmark
Overview
Explore the profile of Marianne Nordsmark including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1907
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skinnerup Byskov C, Mortensen H, Biston M, Broggi S, Butof R, Canters R, et al.
Acta Oncol
. 2025 Mar;
64:406-414.
PMID: 40079654
Purpose: To present results from the trial radiotherapy quality assurance (RTQA) programme of the centres involved in the randomised phase-III PROton versus photon Therapy for esophageal Cancer - a Trimodality...
2.
Spindler K, Jakobsen A, Eriksen J, Fokdal L, Nordsmark M, Thorsen L, et al.
Acta Oncol
. 2025 Jan;
64():1-12.
PMID: 39748655
Background And Purpose: The similarities in biology, treatment regimens and outcome between the different human papillomavirus (HPV) associated squamous cell carcinomas (SCCs) allow for extrapolation of results generated from one...
3.
Kroese T, Bronzwaer S, van Rossum P, Schoppman S, Deseyne P, Van Cutsem E, et al.
Eur J Cancer
. 2024 Apr;
204:114062.
PMID: 38678762
Introduction: The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to provide clinical practice guidelines for the definition, diagnosis, and treatment of esophagogastric oligometastatic disease (OMD). Methods: Guidelines were developed according to...
4.
Baeksgaard Jensen L, Yilmaz M, Nordsmark M, Moller S, Elle I, Ladekarl M, et al.
EClinicalMedicine
. 2024 Mar;
70:102521.
PMID: 38495525
Background: Trifluridine-tipiracil has shown a survival benefit compared with placebo in patients with chemorefractory metastatic esophago-gastric adenocarcinoma. We aimed to compare the efficacy of trifluridine-tipiracil plus bevacizumab vs trifluridine-tipiracil monotherapy...
5.
Sondergaard M, Nordsmark M, Nielsen K, Valentin J, Johnsen S, Poulsen S
Heart Lung Circ
. 2024 Feb;
33(5):664-674.
PMID: 38336543
Background: The cardiovascular disease (CVD) burden among patients with oesophageal cancer (EC) treated with curative intent is unclear. Aim: To determine CVD incidence and all-cause mortality in patients with EC....
6.
Caspers I, Slagter A, Lind P, Sikorska K, Wiklund K, Ponten F, et al.
J Surg Oncol
. 2023 Dec;
129(4):734-744.
PMID: 38073160
Background And Objective: This study aims to investigate the impact of sex on outcome measures stratified by histological subtype in patients with resectable gastric cancer (GC). Methods: A post-hoc analysis...
7.
Kroese T, van Laarhoven H, Schoppman S, Deseyne P, Van Cutsem E, Haustermans K, et al.
Eur J Cancer
. 2023 Mar;
185:28-39.
PMID: 36947929
Background: Local treatment improves the outcomes for oligometastatic disease (OMD, i.e. an intermediate state between locoregional and widespread disseminated disease). However, consensus about the definition, diagnosis and treatment of oligometastatic...
8.
Kroese T, van Rossum P, Nilsson M, Lordick F, Smyth E, Rosati R, et al.
Eur J Surg Oncol
. 2022 Oct;
49(1):21-28.
PMID: 36184420
Background: A uniform definition and treatment for oligometastatic esophagogastric cancer is currently lacking. However, a comprehensive definition of oligometastatic esophagogastric cancer is necessary to initiate studies on local treatment strategies...
9.
Slagter A, Caspers I, van Grieken N, Walraven I, Lind P, Meershoek-Klein Kranenbarg E, et al.
Cancers (Basel)
. 2022 Jun;
14(12).
PMID: 35740628
(1) Background: Perioperative chemotherapy is the current standard treatment for patients with resectable gastric cancer. Based on studies in patients with metastatic gastric cancer, oxaliplatin has replaced cisplatin in the...
10.
Hoffmann L, Mortensen H, Shamshad M, Berbee M, Bizzocchi N, Butof R, et al.
Radiother Oncol
. 2022 May;
172:32-41.
PMID: 35513132
Purpose: To compare dose distributions and robustness in treatment plans from eight European centres in preparation for the European randomized phase-III PROTECT-trial investigating the effect of proton therapy (PT) versus...